A Study of Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergency

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 398 participants.

Also called NCT05783557

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 398 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05783557
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05783557. Randomized; triple masking; primary purpose treatment. Start 2023-05-01 (anticipated); primary completion 2024-12-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergency
Condition
Hypertensive Emergency
Intervention (Drug)
Clevidipine Butyrate Injectable Emulsion
Intervention (Drug)
Cleviprex®
Lead sponsor
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05783557
Content hash
ec108508fe807643c0b607258466377757fdf9b4f6e3ff0ce0b679c536fbb198